4D Molecular Therapeutics, Inc. (FDMT)

Every figure this model derived for FDMT, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 536,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 361,334,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 382,957,000 AssetsCurrent 2026-06-30
current liabilities 47,673,000 LiabilitiesCurrent 2026-06-30
equity 407,659,000 StockholdersEquity 2026-06-30
ocf -156,071,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 92,008,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 20,409,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up FDMT on one particular measure came for.

RatioValue
cash operating margin-186.59
current ratio8.09
current ratio reported8.03
deferred revenue growth-66.23
dilution pct7.4
fcf margin-170.21
growth cv2.0
operating margin-214.24
owner earnings margin-192.39
revenue growth278712.12
revenue growth per share259513.11
roic-236.26
rule of 40278497.88
sbc pct revenue22.18

What to be careful about

What this model itself distrusts about FDMT's figures. Written by the derivation as it ran, not added afterwards.